Jesse2233
Senior Member
- Messages
- 1,942
- Location
- Southern California
Had this thought the other day... I image the answer is probably yes given the wide availability of Suramin in West Africa, the prevalence of both Ebola and African sleeping sickness there, and the possibility a doctor or researcher there has intuitively or inductively connected anti-purinergic therapy to a hypometabolic state.
Since Post Ebola Syndrome may likely be ME (or a very close metabolic end result), knowing the results of potential Suramin treatment in this cohort could give us a kid of preview of Dr Naviaux's upcoming trials. Additionally, anecdotal or reported evidence could perhaps inform Dr Naviaux's dosing schedule and monitoring of side effects
Edit: Interestingly Suramin has been found to inhibit entry of the Ebola virus https://virologyj.biomedcentral.com/articles/10.1186/s12985-016-0607-2
It's unclear what if anything that portends for Post Ebola Syndrome
Since Post Ebola Syndrome may likely be ME (or a very close metabolic end result), knowing the results of potential Suramin treatment in this cohort could give us a kid of preview of Dr Naviaux's upcoming trials. Additionally, anecdotal or reported evidence could perhaps inform Dr Naviaux's dosing schedule and monitoring of side effects
Edit: Interestingly Suramin has been found to inhibit entry of the Ebola virus https://virologyj.biomedcentral.com/articles/10.1186/s12985-016-0607-2
It's unclear what if anything that portends for Post Ebola Syndrome
Last edited: